Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

adg1 - spp11 - cerebral palsy1 - medullary sponge kidney2 - invasive technique1 - abdominal pain2 - radiographic imaging1 - renal vein1 - photodynamic therapy1 - single kidney1 - zytiga5 - glomerular filtration rate4 - prostate cancer cell1 - local anesthesia1 - invasive urologic surgery1 - glucose assorption1 - sphincter deficiency4 - clear cell rcc1 - routine antenatal sonography1 - diabetes-related kidney failure1 - low blood pressure1 - national institutes of health2 - glomerulosclerosis1 - prostate cancer survival1 - pyelolithotomy1 - hyperoxaluria4 - interstitium1 - perineum4 - tgen1 - surgery and radiation therapy1 -